Current as of February 2026. This post will be updated as inventory and testing status changes.
Tirzepatide
Tirzepatide 15mg — In Stock. Current batch has cleared all six parameters of our quality panel. LC/MS/MS identity confirmed. Purity verified. Bioburden, endotoxin, organism ID, and LPS screening all passed. Certificate of Analysis available on request or included with shipment.
Tirzepatide 30mg — In Stock. Same batch, same testing. Full six-parameter panel cleared.
Retatrutide
Retatrutide 15mg — In Stock. Six-parameter quality panel cleared. LC/MS/MS molecular identity confirmed for this triple-agonist compound (GIP/GLP-1/glucagon receptor activity).
Retatrutide 20mg — In Stock. Full panel cleared.
Retatrutide 30mg — In Stock. Full panel cleared.
Retatrutide 60mg — In Stock. Full panel cleared. This is our highest-volume vial size for retatrutide.
Testing Notes
Both compounds are verified through our complete six-parameter quality panel: molecular identity by LC/MS/MS, purity by LC/MS/MS, bioburden by culture, organism identification by PCR, endotoxin by LAL, and gram-negative screening by LPS. We do not release any batch that fails any parameter.
Certificates of Analysis documenting all six test results are included with every shipment. Need a CoA before ordering? Email support@parkplacelabs.com.
All compounds sold by Park Place Peptides are for research use only. Not for human consumption.